Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Cancer Registry (NCR)

Definition A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives - To measure cancer incidence
- To describe cancer by time, place, persons and disease
- To provide a national database for further epidemiological research
Case definition Target cases are:
- Incident cases by year of diagnosis
- Malignant tumors confirmed by histopathology and/or hematology findings
- Cancers of all sites
Sources of data Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting).
1) The capture system: 
The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms:
- Directly from their clinic; or
- Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients
2) The recapture system: 
The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3).
The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor.
The structure is C##.# M####/##, where:
- C##.# specifies the primary site
- M#### specifies the histology
- /## specifies the behavior and the grade of the tumor
Reporting form NCR reporting form
    ...
    137
    ...
ATC Name B/G Ingredients Dosage Form Price
N01AH06 REMIFENTANIL MEDIS G Remifentanil (HCl) - 5mg 5mg Injectable powder 2,576,146 L.L
N01AH06 ULTIVA B Remifentanil (HCl) - 2mg 2mg Injectable powder for solution 1,632,769 L.L
N01AX03 KETAMINE PANPHARMA G Ketamine HCl - 250mg/5ml 250mg/5ml Injectable solution 1,534,668 L.L
N01AX10 PROPOFOL-LIPURO B Propofol - 10mg/ml 1% Injectable emulsion 1,411,035 L.L
N01AX10 DORMIFOR G Propofol - 1% 1% Injectable emulsion 1,081,473 L.L
N01AX10 PROPOFOL 1% MCT/LCT FRESENIUS G Propofol - 1% 1% Injectable emulsion 847,965 L.L
N01BB01 BUPIVACAINE AGUETTANT for spinal anaesthesia G Bupivacaine HCl - 20mg/4ml 20mg/4ml Injectable solution 1,554,826 L.L
N01BB01 BUPIVACAINE HEAVY PANPHARMA G Bupivacaine HCl - 20mg/4ml 20mg/4ml Injectable solution 2,586,897 L.L
N01BB01 BUPIVACAINE AGUETTANT 2.5MG/ML G Bupivacaine HCl - 50mg/20ml 50mg/20ml Injectable solution 2,736,063 L.L
N01BB01 BUPIVACAINE AGUETTANT 5MG/ML G Bupivacaine HCl - 100mg/20ml 100mg/20ml Injectable solution 3,078,743 L.L
N01BB02 AVOCAINE G Lidocaine - 10% 10% Spray 620,855 L.L
N01BB02 LIDOCAINE ARWAN G Lidocaine (HCl) - 0.5% 0.5% Injectable solution 1,995,158 L.L
N01BB02 LIDOCAINE ARWAN G Lidocaine (HCl) - 1% 1% Injectable solution 1,995,158 L.L
N01BB02 LIDOCAINE ARWAN G Lidocaine (HCl) - 1% 1% Injectable solution 1,995,158 L.L
N01BB02 CHLORHYDRATE DE LIDOCAINE RENAUDIN G Lidocaine (HCl) - 10mg/ml 1% Injectable solution 591,291 L.L
N01BB02 LIDOCAINE- ORBUCELL G Lidocaine HCl - 1% 1% Injectable solution 1,787,950 L.L
N01BB02 LIDOCAINE- ORBUCELL G Lidocaine HCl - 2% 2% Injectable solution 1,787,950 L.L
N01BB02 LIDOCAINE PANPHARMA 2% G Lidocaine (HCl) - 20mg/ml 2% Injectable solution 3,398,578 L.L
N01BB02 LIDO-CARE G Lidocaine - 2% 2% Injectable solution 100,788 L.L
N01BB02 ? 2% LIDOCAINE HCL USP G Lidocaine HCl - 2% 2% Injectable solution 255,970 L.L
N01BB03 MEDICAINE 3% SANS VASOCONSTRICTEUR G Mepivacaine HCl - 3% 3% Injectable solution 954,128 L.L
N01BB03 SCANDINIBSA G Mepivacaine HCl - 3% 3% Injectable solution 1,191,988 L.L
N01BB09 ROPIVACAINA MOLTENI G Ropivacaine HCl - 75mg/10ml 7.5mg/ml Injectable solution 2,332,911 L.L
N01BB09 ROPIVACAINE B. BRAUN G Ropivacaine HCl - 75mg/10ml 7.5mg/ml Injectable solution 4,831,114 L.L
N01BB52 DILOCAIN 2% G Lidocaine HCl - 20mg/1.7ml, Epinephrine (bitartrate) - 0.0125mg/1.7ml Injectable solution 2,768,316 L.L
N01BB53 MEDICAINE 2% WITH ADRENALINE G Mepivacaine HCl - 36mg/1.8ml, Epinephrine (tartrate) - 0.032mg/1.8ml Injectable solution 1,652,926 L.L
N01BB54 EMLA B Prilocaine - 25mg/g, Lidocaine - 25mg/g 5% Cream 1,763,121 L.L
N01BB54 PRILA G Prilocaine - 2.5% w/w, Lidocaine - 2.5% w/w Cream 1,057,604 L.L
N01BB58 ARTINIBSA 4% WITH EPINEPHRINE 1/100000 B Articaine HCl - 4%, Epinephrine - 1/100.000 Injectable solution 1,968,729 L.L
N01BB58 SEPTANEST ADRENALINEE B Articaine HCl - 72mg/1.8ml, Adrenaline (tartrate) - 0.033mg/1.8ml 1/100,000 Injectable solution 2,945,703 L.L
    ...
    137
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025